The effect of glial cell line-derived neurotrophic factor in fibrin glue on developing dopamine neurons

Cheng, Henrich; Hoffer, Barry J.; Strömberg, Ingrid; Russell, D A; Olson, Lar̀s

doi:10.1007/bf00242006

Cited by 37 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in the nigrostriatal dopamine system have been documented in vivo in rats, mice, and monkeys under a variety of experimental circumstances (Beck et al 1995(Beck et al , 1996Bowenkamp et al 1995;Cheng et al 1995;Clarkson et al 1995;Gash et al 1995Gash et al , 1996Hoffer et al 1994;Hudson et al 1995;Johansson et al 1995;Kearns and Gash 1995;Krieglstein 1995;Lindner et al 1995;Opacka-Juffry et al 1995;Sauer et al 1995;Shults et al 1996;Strömberg et al 1993;Tomac et al 1995b). GDNF binding has been characterized , and it has been demonstrated that GDNF delivered into the basal ganglia is taken up by dopamine nerve terminals and transported retrogradely to the dopamine cell bodies in the substantia nigra (Tomac et al 1995a).…”

Section: Discussionmentioning

confidence: 95%

Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system

et al. 1996

Self Cite

View full text Add to dashboard Cite

Glial-cell-line-derived neurotrophic factor (GDNF) is a distant member of the transforming growth factor-beta family and has potent neurotrophic effects on several classes of neurons including dopamine neurons and motoneurons. Here, we have used in situ hybridization to describe the development of the cellular expression of GDNF mRNA pre- and postnatally. Consistent with dopaminotrophic activity, GDNF mRNA is expressed in the developing basal ganglia and the olfactory tubercle. It is also found in a thalamic nucleus, in neurons of the substantia innominata, in the developing Purkinje neurons and the developing locus coeruleus area, and in trigeminal brainstem nuclei. In the spinal cord, neuronal expression is found in Clarke's column. GDNF mRNA is also expressed in the dorsal horns during development. Additional GDNF mRNA expression in the head region includes the carotid body, the retina, the vibrissae, the inner ear, the ear canal, and epithelium in the nasal cavity. Prominent expression is also found in the developing teeth. The widespread expression of GDNF in developing skeletal muscle is consistent with trophic activity on alpha-motoneurons. The smooth muscle layers of the gastrointestinal tract are also strongly positive. A very strong signal is found in the outer mesenchyme of the developing metanephric kidney. We conclude that GDNF mRNA is expressed in many different cellular systems inside and outside the central nervous system during development, suggesting multiple functions of GDNF in the developing organism.

show abstract

Section: Discussionmentioning

confidence: 95%

Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system

et al. 1996

Self Cite

View full text Add to dashboard Cite

show abstract

“…This study put GDNF loaded fibrin glue spheres along with pieces of fetal brain tissue into the anterior chambers of rats and documented increased staining of neurons in the group with GDNF versus fibrin glue alone. [32] The breadth of tissue types in these studies indicates the possible realms for fibrin glue beyond clotting and coagulation disciplines.…”

Section: Loaded Factor Drug and Vector Systemsmentioning

confidence: 99%

Fibrin glue as a drug delivery system

Spicer

Mikos

2010

Journal of Controlled Release

163

107

View full text Add to dashboard Cite

Fibrin glue has been used surgically for decades for hemostasis as well as a sealant. It has also been researched as both a gel for cell delivery and a vehicle for drug delivery. The drug delivery applications for fibrin glue span tissue engineering to chemotherapy and involve several mechanisms for drug matrix interactions and control of release kinetics. Additionally, drugs or factors can be loaded in the gel via impregnation and tethering to the gel through covalent linkages or affinity based systems. This review highlights recent research of fibrin glue as a drug delivery vehicle.

show abstract

“…When cells in the striatum were transfected via adenoviral vectors and 6-OHDA later injected into the striatum, approximately 60% of TH+ neurons were preserved in the nigra of GDNF-transfected rats versus approximately 40% in control animals [5]. One novel method to deliver GDNF in the CNS for prolonged local release is to incorporate it in a biodegradable biomaterial such as fibrin glue [12,13]. New approaches for the treatment of PD may also be developed by targeting GDNF receptors or the signalling pathway that is initiated when these receptors are activated.…”

Section: Future Directionsmentioning

confidence: 99%

Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson’s disease

1998

View full text Add to dashboard Cite

Considerable effort has been devoted to the search for molecules that might exert trophic influences on midbrain dopamine neurons, and potentially be of therapeutic value in the treatment of Parkinson's disease. One such candidate is glial cell line-derived neurotrophic factor (GDNF). GNDF is distantly related to the transforming growth factor-beta superfamily and is widely expressed in many neuronal and non-neuronal tissues. GDNF uses a multisubunit receptor system in which GFRalpha-1 and Ret function as the ligand-binding and signalling components, respectively. In addition to its effects on cultured fetal midbrain dopamine neurons, GDNF promotes recovery of the injured nigrostriatal dopamine system and improves motor functions in rodent and nonhuman primate models of Parkinson's disease. Intraventricular, intrastriatal and intranigral routes of administration are efficacious in both models. In parkinsonian nonhuman primates, GDNF treatment improves bradykinesia, rigidity and postural instability. In this model, adult midbrain dopamine neurons stimulated by GDNF show increased cell size, neuritic extent, and expression of phenotypic markers. The neurorestorative effects of a single administration of GDNF last for at least a month and can be maintained in rhesus monkeys by monthly injections. GDNF also induces neuroprotective changes in dopamine neurons, which are active within hours following trophic factor administration in rodents. The powerful neuroprotective and neurorestorative properties of GDNF seen in preclinical studies suggest that trophic factors may play an important role in treating Parkinson's disease.

show abstract

The effect of glial cell line-derived neurotrophic factor in fibrin glue on developing dopamine neurons

Cited by 37 publications

References 33 publications

Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system

Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system

Fibrin glue as a drug delivery system

Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson’s disease

Contact Info

Product

Resources

About